<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04008355</url>
  </required_header>
  <id_info>
    <org_study_id>AZP2006C04</org_study_id>
    <nct_id>NCT04008355</nct_id>
  </id_info>
  <brief_title>A Study to Assess Tolerability, Safety, Pharmacokinetics and Effect of AZP2006 in Patients With PSP</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess Tolerability, Safety, Pharmacokinetics and Effect of AZP2006 on Cerebrospinal Fluid Biomarkers in 36 Patients With Progressive Supranuclear Palsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AlzProtect SAS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AlzProtect SAS</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase 2 study to assess tolerability, safety, pharmacokinetics and effect of AZP2006 at
      different doses versus placebo on cerebrospinal fluid biomarkers in 36 patients with
      progressive supranuclear palsy. The patient study duration is 29 weeks including a washout
      period.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 22, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 22, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number and percentage of patients who prematurely discontinue from the study due to adverse events (AEs)</measure>
    <time_frame>From Day 1 to Day 180</time_frame>
    <description>Incidence in pourcentage of treatment-emergent adverse events observed directly by investigator and adverse event spontaneously reported by the patient using concise medical terminology</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The pharmacokinetics of AZP2006 (12-week treatment period) in plasma, blood, and CSF</measure>
    <time_frame>From Day 1 of Day 84 (12 weeks)</time_frame>
    <description>To determine the Cmax of AZP2006 in plasma, blood, and CSF after single and multiple dose administration, once daily for 12 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The pharmacokinetics of AZP2006 (12-week treatment period) in plasma, blood, and CSF</measure>
    <time_frame>From Day 1 of Day 84 (12 weeks)</time_frame>
    <description>To determine the tmax of AZP2006 in plasma, blood, and CSF after single and multiple dose administration, once daily for 12 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The pharmacokinetics of AZP2006 (12-week treatment period) in plasma, blood, and CSF</measure>
    <time_frame>From Day 1 of Day 84 (12 weeks)</time_frame>
    <description>To determine the kel of AZP2006 in plasma, blood, and CSF after single and multiple dose administration, once daily for 12 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The pharmacokinetics of AZP2006 (12-week treatment period) in plasma, blood, and CSF</measure>
    <time_frame>From Day 1 of Day 84 (12 weeks)</time_frame>
    <description>To determine the Clast of AZP2006 in plasma, blood, and CSF after single and multiple dose administration, once daily for 12 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The pharmacokinetics of AZP2006 (12-week treatment period) in plasma, blood, and CSF</measure>
    <time_frame>From Day 1 of Day 84 (12 weeks)</time_frame>
    <description>To determine the AUC 0-10 of AZP2006 in plasma, blood, and CSF after single and multiple dose administration, once daily for 12 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The pharmacokinetics of AZP2006 (12-week treatment period) in plasma, blood, and CSF</measure>
    <time_frame>From Day 1 of Day 84 (12 weeks)</time_frame>
    <description>To determine the AUC 0-24 of AZP2006 in plasma, blood, and CSF after single and multiple dose administration, once daily for 12 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The pharmacokinetics of AZP2006 (12-week treatment period) in plasma, blood, and CSF</measure>
    <time_frame>From Day 1 of Day 84 (12 weeks)</time_frame>
    <description>To determine the AUC 0-t of AZP2006 in plasma, blood, and CSF after single and multiple dose administration, once daily for 12 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The pharmacokinetics of AZP2006 (12-week treatment period) in plasma, blood, and CSF</measure>
    <time_frame>From Day 1 of Day 84 (12 weeks)</time_frame>
    <description>To determine the t1/2 of AZP2006 in plasma, blood, and CSF after single and multiple dose administration, once daily for 12 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The pharmacokinetics of AZP2006 (12-week treatment period) in plasma, blood, and CSF</measure>
    <time_frame>From Day 1 of Day 84 (12 weeks)</time_frame>
    <description>To determine the tlast of AZP2006 in plasma, blood, and CSF after single and multiple dose administration, once daily for 12 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The pharmacokinetics of AZP2006 (12-week treatment period) in plasma, blood, and CSF</measure>
    <time_frame>From Day 1 of Day 84 (12 weeks)</time_frame>
    <description>To determine the %AUCextra of AZP2006 in plasma, blood, and CSF after single and multiple dose administration, once daily for 12 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The pharmacokinetics of AZP2006 (12-week treatment period) in plasma, blood, and CSF</measure>
    <time_frame>From Day 1 of Day 84 (12 weeks)</time_frame>
    <description>To determine the CL/F of AZP2006 in plasma, blood, and CSF after single and multiple dose administration, once daily for 12 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The pharmacokinetics of AZP2006 (12-week treatment period) in plasma, blood, and CSF</measure>
    <time_frame>From Day 1 of Day 84 (12 weeks)</time_frame>
    <description>To determine the Vd/F of AZP2006 in plasma, blood, and CSF after single and multiple dose administration, once daily for 12 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The pharmacokinetics of AZP2006 (12-week treatment period) in plasma, blood, and CSF</measure>
    <time_frame>From Day 1 of Day 84 (12 weeks)</time_frame>
    <description>To determine the Ctrough of AZP2006 in plasma, blood, and CSF after single and multiple dose administration, once daily for 12 weeks</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Progressive Supranuclear Palsy</condition>
  <arm_group>
    <arm_group_label>60mg/day/84 days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized in this arm will receive 60 mg of study investigational drug AZP2006 once daily during 84 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>80mg/day/10 days followed by 50mg/day/74 days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized in this arm will receive 80 mg of study investigational drug AZP2006 once daily during 10 days followed by 50 mg of study investigational drug AZP2006 once daily during the next 74 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo/84 days</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients randomized in this arm will receive placebo solution once daily during 84 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZP2006 oral solution</intervention_name>
    <description>Once daily intake in the morning</description>
    <arm_group_label>60mg/day/84 days</arm_group_label>
    <arm_group_label>80mg/day/10 days followed by 50mg/day/74 days</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral solution</intervention_name>
    <description>Once daily intake in the morning</description>
    <arm_group_label>Placebo/84 days</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients with probable or possible PSP

          -  Patients must be stable with their medication for at least 30 days prior to the
             inclusion visit.

        Exclusion Criteria:

          -  Any history of clinically significant head trauma or cerebrovascular disease or recent
             history of substance abuse or alcohol abuse and deemed to be clinically significant by
             the Investigator.

          -  History of deep brain stimulator (DBS) surgery other than sham surgery for DBS
             clinical study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe Verwaerde, PhD</last_name>
    <role>Study Director</role>
    <affiliation>AlzProtect SAS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Philippe Verwaerde, PhD</last_name>
    <phone>+33 9 72 64 97 57</phone>
    <email>p.verwaerde@alzprotect.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital Salengro</name>
      <address>
        <city>Lille</city>
        <state>Hauts De France</state>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valerie Santraine</last_name>
      <phone>+33 (0) 3 20 44 59 62</phone>
      <email>Valerie.SANTRAINE@CHRU-LILLE.FR</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Universitaires Pitié Salpêtrière - Charles Foix</name>
      <address>
        <city>Paris</city>
        <state>Ile-de-France</state>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vanessa Brochard</last_name>
      <phone>+33 (0) 1 42 16 57 61</phone>
      <email>vanessa.brochard-ext@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 18, 2019</study_first_submitted>
  <study_first_submitted_qc>July 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 5, 2019</study_first_posted>
  <last_update_submitted>July 15, 2020</last_update_submitted>
  <last_update_submitted_qc>July 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Supranuclear Palsy, Progressive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

